PRELIMINARY PROGRAMME

Replacement and non-replacement therapies in hemophilia A and B
Efficacy of extended half-life products

08.30

Real life data: real benefit. What have we achieved?
TBA

09.00

How to optimize the use of extended half-life product (PK analysis)
Alfonso Iorio (Canada)

09.30

PK-guided management of surgery with extended half-life products
TBA

Safety of replacement therapies (standard and novel) (part I)

10.00

How safety of novel anti-hemophilic drugs should be approached. Known and unknown adverse effects
TBA

10.30

Are Fc – FVIII products less immunogenic? Any new clinical data?
Christoph Königs (Germany)

11.00

Break

Safety of replacement therapies (standard and novel) (part II)

11.30

PEG and long-term toxicity
TBA

12.00

European pharmacovigilance of new products (with special emphasis on pegylated products)
TBA

12.30

Immunogenicity of subcutaneous and intravenous drugs
David Lillicrap (Canada)

13.00

Lunch

14.00

Industry Symposium
TBA

15.00

Industry Lecture
TBA

15.30

Oral Communications

16.30

Break

17.00

New assays for novel anti-hemophilic therapies
TBA

The role of von Willebrand factor in factor VIII immunogenicity

17.30

FVIII peptide presentation to the immune system by VWF modulation
Jan Voorberg (Netherlands)

18.00

High VWF affinity FVIII and immunogenicity
Peter Lenting (France)

18.30

Walking Poster Session